GalXC Plus

WIPO WIPO 2021

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The International trademark GalXC Plus was filed as Figurative mark on 07/14/2021 at the World Intellectual Property Organization.

Logodesign (Wiener Klassifikation)

#Triangles, lines forming an angle #Letters presenting a special form of writing #Colours #Several triangles, juxtaposed, joined or intersecting #Series of letters in different dimensions #Three predominant colours

Trademark Details Last update: May 17, 2023

Trademark form Figurative mark
File reference 1621515
Countries Australia Canada China European Community United Kingdom Japan
Base trademark US No. 90474748, January 19, 2021
Application date July 14, 2021
Expiration date July 14, 2031

Trademark owner

87 Cambridgepark Drive
Cambridge MA 02140
US

Trademark representatives

Two Commerce Square, 2001 Market Street, US

goods and services

05 Oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; oligonucleotide delivery agents for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; oligonucleotide compounds for use in the targeted delivery of RNAi therapy; oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies
42 Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of disorders outside the liver; research and development of oligonucleotide compounds for targeted gene silencing; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections

Trademark history

Date Document number Area Entry
May 10, 2023 2023/19 Gaz CA Rejection
December 15, 2022 2022/51 Gaz JP RAW: Rule 18ter(2)(ii) GP following a provisional refusal
June 2, 2022 2022/22 Gaz JP Rejection
March 10, 2022 2022/10 Gaz EM Rejection
February 22, 2022 2022/8 Gaz CN Rejection
February 2, 2022 2022/5 Gaz GB Rejection
January 12, 2022 2022/3 Gaz AU Rejection
July 14, 2021 2021/40 Gaz US Registration

ID: 141621515